OncoResponse is a clinical stage, privately held immuno-oncology biotech company developing cancer immunotherapies using clues from the immune systems of elite cancer responders. In a broad strategic alliance with MD Anderson Cancer Center, OncoResponse deploys a proprietary B-cell discovery platform to identify and develop novel therapeutics targeting the tumor microenvironment. The company’s lead candidate, OR2805, has entered clinical studies with a unique and transformative approach to the advancement of cancer therapeutics.
OncoResponse is based in Houston, Texas and Seattle, Washington.
Company Details
- Employees
- 11
- Founded
- -
- Address
- 609 Main Street,
- Industry
- Research
- Website
- http://oncoresponse.com
- Keywords
- Manager jobs.
- HQ
- Houston, Texas
Oncoresponse Questions
Oncoresponse's website is http://oncoresponse.com
Oncoresponse's LinkedIn profile is https://www.linkedin.com/company/oncoresponse
Oncoresponse has
11 employees.
View email and phone details for 11
employees at Oncoresponse.
Oncoresponse's industry is
Research
Oncoresponse's top competitors are
Pai Life Sciences Inc.,
Ignyte Bio,
Morphimmune,
Umoja Biopharma,
Immunitybio, Inc.,
Seagen,
Immunome, Inc.,
Notch Therapeutics,
Cg Oncology,
Ipa (Immunoprecise Antibodies).
Oncoresponse's categories are Research
Oncoresponse's founding year is 2016
